We are live on
!
Find out more
CM
Crestline Management Portfolio holdings
AUM
$46.3M
1-Year Est. Return
48.82%
This Fund
S&P 500
This Quarter
Est. Return
+21.79%
1 Year Est. Return
+48.82%
3 Year Est. Return
+52.52%
5 Year Est. Return
+37.91%
10 Year Est. Return
+316.44%
AUM
$1.16B
AUM Growth
+$372M
(+47%)
Cap. Flow
+$132M
Cap. Flow
% of AUM
11.39%
Top 10 Holdings %
Top 10 Hldgs %
68.38%
Holding
232
New
129
Increased
24
Reduced
12
Closed
56
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sana Biotechnology
SANA
|
+$72.8M |
| 2 |
Petrobras Class A
PBR.A
|
+$20.9M |
| 3 |
Ameriprise Financial
AMP
|
+$11.4M |
| 4 |
MetLife
MET
|
+$10.1M |
| 5 |
Wells Fargo
WFC
|
+$7.59M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Denali Therapeutics
DNLI
|
+$114M |
| 2 |
Micron Technology
MU
|
+$7.77M |
| 3 |
UDR
UDR
|
+$5.92M |
| 4 |
Equitable Holdings
EQH
|
+$4.95M |
| 5 |
Lam Research
LRCX
|
+$4.46M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 61.94% |
| 2 | Financials | 15.05% |
| 3 | Materials | 5.33% |
| 4 | Technology | 3.84% |
| 5 | Energy | 2.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Denali Therapeutics
DNLI
$3.65B
| $638M | 55.02% |
8,135,481
-1,849,355
| -19% | -$114M |
|
|
2
Sana Biotechnology
SANA
$871M
| $63.1M | 5.44% |
+3,210,937
| New | +$72.8M |
|
|
3
Petrobras Class A
PBR.A
$111B
| $25M | 2.16% |
+2,120,000
| New | +$20.9M |
|
|
4
Ameriprise Financial
AMP
$48.3B
| $11.3M | 0.97% |
+45,223
| New | +$11.4M |
|
|
5
MetLife
MET
$61.9B
| $9.51M | 0.82% |
+158,863
| New | +$10.1M |
|
6
Travelers Companies
TRV
$78.1B
| $8.53M | 0.74% |
57,000
+43,972
| +338% | +$6.82M |
|
7
American Financial Group
AFG
$11.8B
| $7.96M | 0.69% |
63,828
+33,612
| +111% | +$4.2M |
|
|
8
Wells Fargo
WFC
$261B
| $7.7M | 0.66% |
+170,000
| New | +$7.59M |
|
9
PNC Financial Services
PNC
$99.7B
| $7.63M | 0.66% |
+40,000
| New | +$7.51M |
|
10
American Express
AXP
$227B
| $7.43M | 0.64% |
+45,000
| New | +$7.05M |
|
11
American International
AIG
$41.7B
| $7.38M | 0.64% |
155,000
+96,014
| +163% | +$4.75M |
|
12
Hartford Financial Services
HIG
$38.9B
| $7.13M | 0.62% |
115,083
+44,432
| +63% | +$2.91M |
|
13
Zurn Elkay Water Solutions
ZWS
$8.38B
| $7.01M | 0.6% |
+290,640
| New | +$6.99M |
|
14
Morgan Stanley
MS
$331B
| $6.88M | 0.59% |
+75,000
| New | +$6.43M |
|
15
Goldman Sachs
GS
$300B
| $6.83M | 0.59% |
+18,000
| New | +$6.44M |
|
16
Franco-Nevada
FNV
$41.1B
| $6.64M | 0.57% |
45,800
+28,800
| +169% | +$4.17M |
|
17
International Flavors & Fragrances
IFF
$20.2B
| $6.63M | 0.57% |
+44,400
| New | +$6.37M |
|
18
ArcelorMittal
MT
$52.9B
| $6.4M | 0.55% |
206,000
+10,000
| +5% | +$310K |
|
19
Brown & Brown
BRO
$23.6B
| $6.35M | 0.55% |
+116,484
| New | +$5.99M |
|
|
MRSH
20
Marsh
MRSH
$90.5B
| $6.33M | 0.55% |
+45,000
| New | +$6.03M |
|
21
Vale
VALE
$64.1B
| $6.14M | 0.53% |
269,000
-72,000
| -21% | -$1.51M |
|
22
Advanced Micro Devices
AMD
$776B
| $6.11M | 0.53% |
+65,000
| New | +$5.25M |
|
23
Alcoa
AA
$11.9B
| $5.86M | 0.51% |
159,098
+33,598
| +27% | +$1.22M |
|
24
Lincoln National
LNC
$8.72B
| $5.86M | 0.51% |
93,227
+15,920
| +21% | +$1.05M |
|
|
ARNC
25
DELISTED
Arconic Corporation
ARNC
| $5.51M | 0.48% |
154,674
+118,670
| +330% | +$3.92M |
|
Similar funds
MCMC
RRC
PCM
NPCM
FCM
EGI
IPHI
SM
Crestline Management's Q2 2021 Portfolio in Review
As of Q2 2021, Crestline Management held 232 positions worth $1.16B, up 47% from $788M the previous quarter. Its ten largest holdings account for 68% of the portfolio.
Crestline Management deployed $132M of net new capital in Q2 2021, opening 129 new positions and adding to 24 existing holdings. Its largest new stake was Sana Biotechnology: 3,210,937 shares worth $63.1M.
By sector, the portfolio is most concentrated in Healthcare at 62% of assets, down from 72% a quarter earlier, followed by Financials and Materials.
On the sell side, the largest reduction was Denali Therapeutics, an estimated $114M trimmed.
- Crestline Management's largest Q2 2021 buy was Sana Biotechnology: 3,210,937 shares worth $63.1M.
- Crestline Management added most to Travelers Companies in Q2 2021, an estimated $6.82M increase.
- Crestline Management's biggest Q2 2021 reduction was Denali Therapeutics, cutting an estimated $114M.
- Crestline Management fully exited Micron Technology in Q2 2021, selling an estimated $7.77M.
- Crestline Management's ten largest holdings make up 68% of its $1.16B portfolio in Q2 2021.
- Crestline Management opened 129 new positions and closed 56 in Q2 2021.
- Crestline Management's portfolio value rose 47% quarter-over-quarter to $1.16B.
Based on Crestline Management's 13F filing for Q2 2021, filed 13 Aug 2021.